Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  cancer  clinical  company  data  dec  december  marketwired dec  marketwired nov  marketwired  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Tue, 06 Dec 2016 02:58:07 EST

Copyright: Copyright: (C) Marketwired
 



Hutchison China Meditech Limited: HMPL-523 Pre-clinical Data Presented at ASH

Tue, 06 Dec 2016 02:43:42 EST

HONG KONG, CHINA--(Marketwired - Dec 6, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Acasti Pharma annonce un placement proposé d'unités

Mon, 05 Dec 2016 17:40:52 EST

LAVAL, QUÉBEC--(Marketwired - 5 déc. 2016) -




Acasti Pharma Announces Proposed Offering of Units

Mon, 05 Dec 2016 17:37:30 EST

LAVAL, QUEBEC--(Marketwired - Dec. 5, 2016) -




Ogilvy CommonHealth Worldwide wins silver at 2016 Clio Health Awards

Mon, 05 Dec 2016 16:33:35 EST

PARSIPPANY, NJ--(Marketwired - Dec 5, 2016) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced the organization's Sydney-based office, Ogilvy CommonHealth Asia Pacific, has won a silver award at the 2016 Clio Health Awards competition.




UniQuest and CCRM sign international deal to develop treatment for chemotherapy-induced neutropenia

Mon, 05 Dec 2016 14:00:00 EST

TORONTO, ON and BRISBANE, AUSTRALIA--(Marketwired - December 05, 2016) - Patients at risk of life-threatening infections following chemotherapy could benefit from a new cell-based treatment developed from University of Queensland research.




3D Signatures Adds Leading Commercial Diagnostics Lab Executive to Advisory Board

Mon, 05 Dec 2016 12:16:30 EST

WINNIPEG, MB--(Marketwired - December 05, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce the appointment of Mr. Nigel Terrett to 3DS' Business Advisory Board ("BAB"). Mr. Terrett will provide the Company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform. Mr. Terrett brings extensive commercial lab experience to 3DS which includes executive roles with several major commercial labs and electronic health record companies such as Excelleris Technologies, Lifelabs Inc. and MDS Diagnostics Inc.




Digipath, Inc. to Hold Corporate Update Conference Call

Mon, 05 Dec 2016 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Dec 5, 2016) -  Digipath, Inc. (OTCQB: DIGP), an independent cannabis lab testing and media firm, is pleased to announce that it will hold a corporate update conference call on Wednesday, December 7th, at 4:15pm ET. The purpose of the call is to provide an update on Digipath's organic growth strategy, acquisition strategy, developments in the Nevada market post recreational legalization and the Company's expanding technological capabilities.




GeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses

Mon, 05 Dec 2016 09:00:00 EST

ATLANTA, GA--(Marketwired - Dec 5, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will give a talk at the Hemorrhagic Fever Viruses conference sponsored by the Keystone Symposia on Molecular and Cellular Biology. The conference is being held on December 4-8 in Santa Fe, New Mexico.




BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory

Mon, 05 Dec 2016 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC--(Marketwired - December 05, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company will present the latest development update for BriaVaxT, the Company's proprietary vaccine for advanced breast cancer, at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Additionally, the Company signed a service agreement contract with the Terasaki Foundation Laboratory, a leading non-profit research institution in the area of organ transplantation and immunology, based in Los Angeles.







Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting

Sat, 03 Dec 2016 12:00:00 EST

SAN DIEGO, CALIFORNIA--(Marketwired - Dec. 3, 2016) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, TTI-621, in patients with relapsed or refractory hematologic malignancies, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego.




New Advanced Antimicrobial Stewardship Solution from Wolters Kluwer Helps Healthcare Organizations Improve Clinical Outcomes, Reduce Costs

Fri, 02 Dec 2016 09:30:00 EST

Expanded Pharmacy OneSource Sentri7 Offering Powers High-Performing Antimicrobial Stewardship Programs to Address Growing Concerns Over Resistant Organisms




Chief Science Officer Explains How Digipath Labs Enables True, Standardized Definition and Identification of Cannabis Strains

Fri, 02 Dec 2016 09:00:00 EST

LAS VEGAS, NV--(Marketwired - Dec 2, 2016) - Digipath, Inc. (OTCQB: DIGP) ("Digipath" or the "Company"), an independent cannabis lab testing and media firm, is pleased to provide an overview of Digipath Labs' vision for establishing classification of cannabis strains based on science and not colloquialism.




eWellness Announces Signing of Initial Third Party PT Clinic for its PHZIO Telemedicine Platform

Fri, 02 Dec 2016 08:45:00 EST

CULVER CITY, CA--(Marketwired - Dec 2, 2016) - eWellness Healthcare Corporation, (OTCQB: EWLL) is the first physical therapy telemedicine company to offer insurance reimbursable real-time distance monitored physical therapy (PT) treatments. The Company is pleased to announce the Company successfully signed its initial 3rd party PT clinic for the use of its PHZIO Tele- rehabilitation Platform. The agreement is with Back to Motion PT located in Denver Colorado. Back to Motion PT is one of our current universe of up to 30 beta site PT clinics to begin using our PHZIO system. The Company has a significant backlog of PT clinics who have indicated a high interest in using our PHZIO platform.




Quark Venture Invests $4 Million in A New Technology That Harnesses the Body's Natural Immune System to Combat Disease

Thu, 01 Dec 2016 12:27:45 EST

GV and Quark Venture Join NanoDimension, Polaris Partners in supporting SQZ Biotech's breakthrough cell engineering technology




The Alliance for Regenerative Medicine Commends Passage of 21st Century Cures Act, Inclusion of Regenerative Medicine-Specific Provisions

Thu, 01 Dec 2016 10:31:01 EST

WASHINGTON, DC--(Marketwired - Dec 1, 2016) -  The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, commends the U.S. House of Representatives' bipartisan passage of the 21st Century Cures Act.




IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product

Thu, 01 Dec 2016 09:56:08 EST

SAINT-LAURENT, CANADA--(Marketwired - Dec. 1, 2016) - IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today strengthened its relationship with Chemo Group ("Chemo") by signing a term sheet for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. According to Global Data, worldwide sales in 2015 of the CNS related product exceeded $4 billion.




Genetic Technologies Announces Offering of USD 6.0 Million of American Depository Shares

Thu, 01 Dec 2016 09:07:53 EST

MELBOURNE, AUSTRALIA--(Marketwired - Dec 1, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced that it has entered into a definitive agreement with U.S. institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 4,800,000 American Depositary Shares ("ADSs"), each representing one hundred and fifty (150) of the Company's Ordinary Shares, at a weighted average price of $1.25 per ADS. The Company will receive gross proceeds of approximately USD 6.0 million, before deducting customary offering expenses.




GeoVax Observes World AIDS Day

Thu, 01 Dec 2016 09:00:00 EST

Everyone Encouraged to Get Tested for HIV




PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

Thu, 01 Dec 2016 09:00:00 EST

Company Aiming to Produce 6-Month Breakthrough Data




Crystal Research Associates, LLC Issues Executive Informational Overview on Hemispherx Biopharma, Inc.

Thu, 01 Dec 2016 08:30:00 EST

NEW YORK, NY--(Marketwired - December 01, 2016) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Hemispherx Biopharma, Inc. (NYSE MKT: HEB). The full 60-page report is available on Crystal Research Associates' website at www.crystalra.com.




Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

Thu, 01 Dec 2016 08:00:00 EST

SEATTLE, WA--(Marketwired - Dec 1, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.




Pieris Pharmaceuticals Appoints Claude Knopf as Chief Business Officer

Thu, 01 Dec 2016 08:00:00 EST

BOSTON, MA--(Marketwired - December 01, 2016) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today announced that it has appointed Claude Knopf as Senior Vice President and Chief Business Officer. Mr. Knopf is an accomplished executive in the biotech industry and brings to Pieris a demonstrable track record of success in strategy, corporate development, licensing, alliance management, marketing and sales spanning more than two decades.




Stellar Biotechnologies to Present at the LD Micro Main Event Investor Conference

Thu, 01 Dec 2016 07:45:00 EST

LOS ANGELES, CA--(Marketwired - Dec 1, 2016) - Stellar Biotechnologies, Inc. (NASDAQ: SBOT), the leader in sustainable manufacture of a key protein utilized in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, today announced that Stellar President and CEO Frank Oakes will present at the 9th Annual LD Micro Main Event investor conference to be held December 6-8, 2016 in Los Angeles, California.




Xtalks Announces its December 2016 Webinars

Thu, 01 Dec 2016 07:00:00 EST

TORONTO, ON--(Marketwired - December 01, 2016) - Upcoming free, educational webinars from Xtalks Life Sciences will feature topics on ICH E6 (R2),Sales Enablement Strategy, Immunotherapy, Big Data, Orphan Drug Development and Remote Monitoring.




Dynavax to Webcast Cancer R&D Day on December 9, 2016

Thu, 01 Dec 2016 07:00:00 EST

BERKELEY, CA--(Marketwired - December 01, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional investors, will be webcast live and can be found in the Investor section of the company's website at www.dynavax.com.




Vernalis plc: AGM Statement

Thu, 01 Dec 2016 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 1, 2016) - Vernalis plc (LSE: VER) (OTC PINK: VNLPY)




Pegasystems Named Silver Winner for Best New Product of the Year in Best in Biz Awards 2016

Wed, 30 Nov 2016 12:00:00 EST

Pega Customer Decision Hub honored for advanced decisioning and analytics capabilities




AXIM Biotech Looks to Unlock Value in 2017 -- SECFilings.com

Wed, 30 Nov 2016 12:00:00 EST

REDONDO BEACH, CA--(Marketwired - Nov 30, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the major advancements in 2016 for AXIM Biotechnologies (OTCQB: AXIM) and the potential catalysts for the company in the upcoming year.




TEC Edmonton's Randy Yatscoff wins Startup Canada National Lifetime Achievement award

Wed, 30 Nov 2016 10:00:00 EST

Adam Chowaniec award recognizes outstanding impact and legacy in Canadian Entrepreneurship




Advantis Corp. Amstercan Sales Increase Three-Fold

Wed, 30 Nov 2016 09:26:00 EST

NEWPORT BEACH, CA--(Marketwired - Nov 30, 2016) - ADVANTIS CORPORATION (OTC PINK: ADVT), announced that Speedweed, California's Largest marijuana delivery service, placed their first product reorder this week. The company has tripled its previous order and expects to purchase two to three hundred Amstercans each month.




Hamilton Thorne to Present at the 2016 LD Micro Main Event

Wed, 30 Nov 2016 08:30:00 EST

BEVERLY, MA and TORONTO, ON--(Marketwired - Nov 30, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets announced today announced that it will be presenting at the 9th annual LD Micro Main Event (www.ldmicro.com), on Wednesday, December 6, 2016 at 2:30 pm Pacific Time (5:30 pm Eastern Time), at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.




Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study

Wed, 30 Nov 2016 07:30:00 EST

TORONTO, ON--(Marketwired - Nov 30, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration ("FDA") has accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin.




Dynavax to Present Clinical Data from Immuno-oncology Product Candidate, SD-101

Wed, 30 Nov 2016 07:00:00 EST

Data to be Presented at ASH Annual Meeting on Sunday, December 4th, in San Diego




Hutchison China Meditech Limited: Exercise of Share Options

Wed, 30 Nov 2016 03:44:06 EST

HONG KONG, CHINA--(Marketwired - Nov 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Hutchison China Meditech Limited: Total Voting Rights

Wed, 30 Nov 2016 03:40:21 EST

HONG KONG, CHINA--(Marketwired - Nov 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)




Natural Remedy for Common Cold, Myrtol(R) 300 Available on Walmart Marketplace

Tue, 29 Nov 2016 12:43:11 EST

Recently Launched in the U.S., Myrtol(R) 300 Targets Value Buyers on Expanding E-commerce Platform




3M ESPE, DENTSPLY, Kerr Lead U.S. Dental Materials Market Due to Extensive Product Portfolios

Tue, 29 Nov 2016 12:30:52 EST

The U.S. dental materials market is projected to exceed $1.8 billion by 2023; the market includes dental cements, impression materials, direct and temporary restoratives, bonding agents, core build-up materials and anesthetic materials




Medical Marijuana, Inc.'s Investment Axim(R) Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

Tue, 29 Nov 2016 12:00:00 EST

Company's Major Investment company Announces Filing of Protection for Proprietary Method of THC Extraction that will Achieve Highest THC Purity Level on the Market




Quidel Receives FDA Clearance for Its New Solana(R) Molecular Assay for the Detection of Herpes Simplex Virus 1+2 and Varicella Zoster Virus

Tue, 29 Nov 2016 10:00:00 EST

SAN DIEGO, CA--(Marketwired - November 29, 2016) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Solana® HSV-1+2/VZV Assay for the qualitative detection and differentiation of herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus DNA isolated and purified from cutaneous or mucocutaneous lesion samples obtained from symptomatic patients suspected of active herpes simplex virus 1, herpes simplex virus 2 and/or varicella-zoster infection.




PCI Synthesis Wins Best NCE Manufacturer in 2016

Tue, 29 Nov 2016 09:15:00 EST

2016 saw more industry recognition and new lines of business




Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin(TM)

Tue, 29 Nov 2016 09:00:00 EST

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - November 29, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL) is pleased to report preliminary pre-clinical results demonstrating anti-cancer activity of ImmucinT in combination with checkpoint inhibitors. Furthermore, Vaxil's scientists have made significant progress for Orphan Designated product ImmucinT in demonstrating its ability to act as a neo-antigen, with potential to strongly stimulate the immune system.




APC Invents Quantitative Method for Assessing Pattern of Antibody Labeling Impacting the Emerging, Rapidly Growing Market for Antibody-Drug Conjugates (ADC)

Tue, 29 Nov 2016 09:00:00 EST

VANCOUVER, BC--(Marketwired - November 29, 2016) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce that it has invented a measurable basis for evaluating antibody labeling that provides key information on the pattern of labeling. The technology provides a means of sorting labeling entities according to the degree of selective labeling resulting from modification of a target antibody for conjugation. The methodology produces a rank order of candidate antibodies carrying antibody connectors for linkage to payloads such as drugs or toxins which should aid decision-making in ADC development. Immense growth is expected for the therapeutic antibody market which is estimated to reach nearly $125 Billion USD by the year 2020 (The therapeutic monoclonal antibody market: Ecker et al. MAbs 2015, Volume 7, ppgs 9-14.).




Cell MedX (CMXC) Advances the Power of Microcurrents -- SECFilings.com

Tue, 29 Nov 2016 08:59:05 EST

REDONDO BEACH, CA--(Marketwired - Nov 29, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering how Cell MedX Corp. (OTCQB: CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.




BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax(TM)

Tue, 29 Nov 2016 08:30:00 EST

BERKELEY, CA and VANCOUVER, BC--(Marketwired - November 29, 2016) - BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) as basis for potential future commercialization of tests for identifying patients with a high likelihood of responding favorably to the Company's lead product candidate, BriaVaxT, and/or other whole-cell cancer vaccines.




Phase 4 Pharmaceutical Studies Lean on Medical Affairs for Strategic Planning

Tue, 29 Nov 2016 08:17:00 EST

RESEARCH TRIANGLE PARK, NC--(Marketwired - November 29, 2016) - Medical affairs functions are an ideal candidate to head post-marketing study strategy, according to new research published by pharmaceutical business intelligence firm Cutting Edge Information.




Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

Tue, 29 Nov 2016 07:30:00 EST

Dermatomyositis is the 2nd indication to have one year open-label extension study with JBT-101




New Webinar Hosted by Xtalks with Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Tue, 29 Nov 2016 07:00:00 EST

Combinatorial CD8+ and PDL1+ Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab




Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH

Tue, 29 Nov 2016 07:00:00 EST

TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) - Trillium Therapeutics Inc. (TSX:TR)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) on Monday, Dec. 5, 2016, to discuss the poster presentation on its lead drug candidate, TTI-621, at the American Society of Hematology (ASH) 58th Annual Meeting in San Diego. Trillium will present initial clinical data from its ongoing TTI-621 hematologic malignancy Phase 1 trial at ASH.




Genetic Technologies Limited and The University of Melbourne Enter into Exclusive Worldwide License Agreement to Develop Colorectal Cancer Risk Assessment Test

Tue, 29 Nov 2016 05:30:00 EST

MELBOURNE, AUSTRALIA--(Marketwired - Nov 29, 2016) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a molecular diagnostics company and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, today announced the signing of an exclusive worldwide license agreement with The University of Melbourne for the development and commercialisation of a novel colorectal cancer (CRC) risk assessment test.